4 results
Evaluate the effects of CER-001 - adminstered as iv infusion - on plaque size/burden in arteries, plaque inflammation in the artery wall and the rate of cholesterol transport in the body
To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.
To primary objective is to evaluate the clinical safety and performance of GATT-Patch in open liver surgery, in order to collect the necessary data to assess whether GATT-Patch meets the general safety and performance requirements for its CE marking…
In phase I safety and pharmacological properties of GDC-0032 in combination with tamoxifen in patients with advanced solid tumors will be investigated. The effectiveness of GDC-0032 in combination with tamoxifen will be studied in patients with…